OMCL Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$59.29median target· current $35.37 (+67.6%)8 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio42.11Forward 29.50
EPS (TTM)$0.84333.3% YoY
Profit margin3.1%HEALTHCARE
Market cap$1.61BSmall cap
Valuation
- Forward P/E
- 29.50
- PEG ratio
- 15.40
- P/B
- 1.25
- P/S (TTM)
- 1.29
- EV/EBITDA
- 10.57
Profitability & growth
- ROE (TTM)
- 3.1%
- Operating margin
- 10.9%
- Revenue growth YoY
- 7.5%
- Dividend yield
- —
- Beta
- 0.97
Last earnings
Jul 30, 2026 · Estimate $0.31 · Reported $0.70
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Omnicell Inc
Company profileOmnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
Classification
- Sector
- Healthcare
- Industry
- Health Information Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 4220 NORTH FREEWAY, FORT WORTH, TX
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$1.61B
Shares outstanding$45.5M
52W high$55.00
52W low$29.06
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent